PITTSBURGH, Nov. 29 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Glimepiride Tablets, 1 mg, 2 mg, and 4 mg. Glimepiride Tablets are the AB-rated generic equivalent of Aventis Pharmaceuticals' Amaryl^® Tablets, which had U.S. sales of approximately $348 million for the 12-month period ending June 30, 2005, according to IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
11/29/2005
CONTACT: Media, Patrick Fitzgerald, or Investors, Kris King, both of


Mylan Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com
(MYL)